2023
A pilot randomized controlled trial of ketamine in Borderline Personality Disorder
Fineberg S, Choi E, Shapiro-Thompson R, Dhaliwal K, Neustadter E, Sakheim M, Null K, Trujillo-Diaz D, Rondeau J, Pittaro G, Peters J, Corlett P, Krystal J. A pilot randomized controlled trial of ketamine in Borderline Personality Disorder. Neuropsychopharmacology 2023, 48: 991-999. PMID: 36804489, PMCID: PMC10209175, DOI: 10.1038/s41386-023-01540-4.Peer-Reviewed Original ResearchConceptsBorderline personality disorderSecondary outcome measuresOutcome measuresSocio-occupational functioningSuicidal ideationPilot studyTrial of ketaminePersonality disorderInfusion of ketaminePrimary outcome measureEffects of ketamineMidazolam groupAdverse eventsKetamine groupClinical benefitMood symptomsKetamineFDA approvalDrug midazolamInfusionBPD symptomsLarger studyDepressed moodSymptomsChronic mood
2005
Effects of smoking and smoking abstinence on cognition in adolescent tobacco smokers
Jacobsen LK, Krystal JH, Mencl WE, Westerveld M, Frost SJ, Pugh KR. Effects of smoking and smoking abstinence on cognition in adolescent tobacco smokers. Biological Psychiatry 2005, 57: 56-66. PMID: 15607301, DOI: 10.1016/j.biopsych.2004.10.022.Peer-Reviewed Original ResearchConceptsAdolescent smokersVerbal memoryTobacco cravingAdolescent daily smokersNicotine withdrawalAdolescent tobacco smokersDaily tobacco smokersDivided attentionVerbal learningCognitive enhancementMemory performanceSustained attentionCognitive performanceGeneral intelligenceAdolescent nonsmokersPerformance decrementsParental educational attainmentFemale smokersDepressed moodMemoryAffective symptomsDaily smokersRecency of smokingTobacco smokersEarly age
1999
Neurotransmitter alterations in PTSD: catecholamines and serotonin.
Southwick SM, Paige S, Morgan CA, Bremner JD, Krystal JH, Charney DS. Neurotransmitter alterations in PTSD: catecholamines and serotonin. Seminars In Clinical Neuropsychiatry 1999, 4: 242-8. PMID: 10553029, DOI: 10.153/scnp00400242.Peer-Reviewed Original ResearchConceptsPost-traumatic stress disorderIntrusive memoriesLevel of alertnessSelective attentionAuditory remindersLife-threatening stimuliStress disorderCatecholamine dysregulationUrine catecholamine excretionExaggerated reactivityDepressed moodExaggerated startlePlatelet paroxetine bindingSerotonergic dysregulationAggressionClinical efficacyImpulsivityMotor outputBlunted prolactin responseMemoryMoodSerotonin reuptake inhibitorsAdrenergic receptor numberCentral catecholamine neuronsCentral nervous system
1992
Chronic 3,4-Methylenedioxymethamphetamine (MDMA) Use: Effects on Mood and Neuropsychological Function?
Krystal J, Price L, Opsahl C, Ricaurte G, Heninger G. Chronic 3,4-Methylenedioxymethamphetamine (MDMA) Use: Effects on Mood and Neuropsychological Function? The American Journal Of Drug And Alcohol Abuse 1992, 18: 331-341. PMID: 1357957, DOI: 10.3109/00952999209026070.Peer-Reviewed Original ResearchConceptsNeuropsychological functionMDMA useChronic MDMA useWechsler Memory ScaleLeast mild impairmentMemory ScaleNeuropsychological batteryTime of testingMood effectsCognitive functionMemory deficitsMethylenedioxymethamphetamine (MDMA) useDepressed moodMood regulationPreliminary evidenceDeficitsMild impairmentClinical criteriaClinical examinationPreliminary findingsSelective serotoninMoodModerate impairmentAffective disordersPossible detrimental effects